A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

This study has been completed.
Information provided by (Responsible Party):
Trius Therapeutics, Inc.
ClinicalTrials.gov Identifier:
First received: October 26, 2011
Last updated: March 17, 2015
Last verified: March 2015

The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus placebo on QTcF.

Condition Intervention Phase
Healthy Volunteer
Drug: TR-701 FA 1200 mg
Drug: Moxifloxacin 400 mg
Drug: TR-701 FA 200 mg plus Placebo
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver)
Official Title: A Phase 1 Blinded, Placebo-controlled Crossover Study to Evaluate the Effects of Oral TR 701 Free Acid on the Electrocardiogram

Resource links provided by NLM:

Further study details as provided by Trius Therapeutics, Inc.:

Primary Outcome Measures:
  • QTcF Change from Baseline [ Time Frame: 24 Hours ] [ Designated as safety issue: No ]
    Time-matched, placebo adjusted change from the baseline QTcF (ΔΔQTcF).

Enrollment: 48
Study Start Date: November 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Moxifloxacin 400 mg
Not applicable
Drug: Moxifloxacin 400 mg
1 tablet 400 mg Moxifloxacin
Experimental: TR-701 FA 1200 mg
Not applicable
Drug: TR-701 FA 1200 mg
6 tablet of T-701 FA
Other Name: Tedizolid
Experimental: TR-701 FA 200 mg plus Placebo
Not applicable
Drug: TR-701 FA 200 mg plus Placebo
1 tablet of TR-701 FA with 5 tablet placebo
Other Name: Tedizolid
Placebo Comparator: Placebo
Not applicable
Drug: Placebo
6 placebo tablets

Detailed Description:

To assess the effects of a single therapeutic (200 mg) and supratherapeutic of oral TR-701 free acid (FA) versus placebo on QT interval corrected for heart rate using Fridericia's formula (QTcF) in healthy subjects.


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female subjects between 18 and 45 years of age, inclusive.
  • Healthy males and females with no clinically significant abnormalities.
  • Body mass index ≥18.0 kg/m2 and ≤30.0 kg/m2

Exclusion Criteria:

  • Sustained supine systolic blood pressure >140 or <100 mmHg or a diastolic blood pressure >90 or <60 mmHg at the Screening and Day 1 Visit.
  • Abnormal ECG at Screening or Day -1 Visits indicating a second or third-degree atrioventricular block, or QRS >110 msec, QTcF >450 msec for males and >470 msec for females, PR interval >200 msec, or any rhythm other than sinus rhythm which is interpreted by the Investigator as clinically significant - History of unexplained infections or current signs of infection
  • History of risk factors for Torsades de Pointes, including unexplained syncope, known Long QT Syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalemia, hypercalcemia, hypomagnesemia, or family history of Long QT Syndrome or Brugada Syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01461460

United States, Texas
Trius Investigator
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Trius Therapeutics, Inc.
Study Chair: Philippe G Prokocimer, MD Trius Therapeutics
  More Information

No publications provided

Responsible Party: Trius Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01461460     History of Changes
Other Study ID Numbers: TR701-115
Study First Received: October 26, 2011
Last Updated: March 17, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Trius Therapeutics, Inc.:

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on March 26, 2015